Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naïve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents -

Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naïve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents
Information type: Randomised controlled trials
Source: Diabetes Care
Specialities: Diabetes
Summary
In patients with type 2 diabetes and HbA1c levels ≥7.5% and ≤10.0% despite metformin alone or two or more oral antidiabetics, add-on prandial Technosphere inhaled insulin (Afrezza®) reduced HbA1c by −0.4% (95% CI −0.57% to −0.23%) compared to placebo (P<0.0001).
UKMi comment
Afrezza® is an ultra-rapid acting human insulin utilising Technosphere® drug delivery technology - Technosphere particles loaded with insulin change from powder to liquid upon contact with the neutral pH of the alveoli surface deep in the lung. It was licensed in the US in June 2014 but has not yet been approved for use in the EU or UK.
Related links: